Trial Profile
A Phase I, Open-label, 2-sequence, Cross-over, Pharmacokinetic (PK) Study to Evaluate the Effect of the Food and to Identify the Metabolism of Fluzoparib in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Fuzuloparib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
- 27 Feb 2017 New trial record